These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 1381571)
1. [High-dose adjuvant chemotherapy with peripheral blood stem cell transplantation for breast cancer with poor prognosis--a pilot study]. Maruyama F; Ezaki K; Miyazaki H; Wakita M; Maeda H; Nomura T; Tsuzuki M; Sobue R; Okamoto M; Matsui T Gan To Kagaku Ryoho; 1992 Sep; 19(11):1859-65. PubMed ID: 1381571 [TBL] [Abstract][Full Text] [Related]
2. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878 [TBL] [Abstract][Full Text] [Related]
3. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection. Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627 [TBL] [Abstract][Full Text] [Related]
4. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100 [TBL] [Abstract][Full Text] [Related]
6. Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer. Menichella G; Pierelli L; Scambia G; Salerno G; Benedetti Panici P; Foddai ML; Serafini R; Puglia G; Lai M; Ciarli M Bone Marrow Transplant; 1994 Dec; 14(6):907-12. PubMed ID: 7536071 [TBL] [Abstract][Full Text] [Related]
7. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105 [TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer. deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672 [TBL] [Abstract][Full Text] [Related]
9. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956 [TBL] [Abstract][Full Text] [Related]
10. [Mega-dose chemotherapy with peripheral blood stem cell transplantation (PBS-CT) for small cell lung cancer (SCLC)]. Chou T; Yokoyama A; Yoshizawa H; Hoshino M; Ebe T; Kurita Y; Arakawa M Gan To Kagaku Ryoho; 1995 Oct; 22(12):1741-8. PubMed ID: 7574804 [TBL] [Abstract][Full Text] [Related]
11. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
12. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer. Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037 [TBL] [Abstract][Full Text] [Related]
14. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma. Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768 [TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628 [TBL] [Abstract][Full Text] [Related]
16. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396 [TBL] [Abstract][Full Text] [Related]
17. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Waller CF; von Lintig F; Daskalakis A; Musahl V; Lange W Bone Marrow Transplant; 1999 Jul; 24(1):19-24. PubMed ID: 10435729 [TBL] [Abstract][Full Text] [Related]
18. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment. Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359 [TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
20. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]